全文获取类型
收费全文 | 7389篇 |
免费 | 451篇 |
国内免费 | 284篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 97篇 |
妇产科学 | 95篇 |
基础医学 | 838篇 |
口腔科学 | 27篇 |
临床医学 | 511篇 |
内科学 | 1341篇 |
皮肤病学 | 69篇 |
神经病学 | 271篇 |
特种医学 | 130篇 |
外国民族医学 | 2篇 |
外科学 | 441篇 |
综合类 | 1163篇 |
预防医学 | 899篇 |
眼科学 | 50篇 |
药学 | 1581篇 |
2篇 | |
中国医学 | 430篇 |
肿瘤学 | 164篇 |
出版年
2024年 | 79篇 |
2023年 | 116篇 |
2022年 | 185篇 |
2021年 | 207篇 |
2020年 | 182篇 |
2019年 | 146篇 |
2018年 | 182篇 |
2017年 | 166篇 |
2016年 | 223篇 |
2015年 | 191篇 |
2014年 | 401篇 |
2013年 | 527篇 |
2012年 | 372篇 |
2011年 | 447篇 |
2010年 | 340篇 |
2009年 | 343篇 |
2008年 | 363篇 |
2007年 | 391篇 |
2006年 | 301篇 |
2005年 | 290篇 |
2004年 | 252篇 |
2003年 | 253篇 |
2002年 | 194篇 |
2001年 | 164篇 |
2000年 | 189篇 |
1999年 | 192篇 |
1998年 | 172篇 |
1997年 | 137篇 |
1996年 | 126篇 |
1995年 | 129篇 |
1994年 | 119篇 |
1993年 | 99篇 |
1992年 | 85篇 |
1991年 | 82篇 |
1990年 | 57篇 |
1989年 | 47篇 |
1988年 | 44篇 |
1987年 | 35篇 |
1986年 | 23篇 |
1985年 | 39篇 |
1984年 | 38篇 |
1983年 | 28篇 |
1982年 | 23篇 |
1981年 | 12篇 |
1980年 | 14篇 |
1979年 | 19篇 |
1978年 | 16篇 |
1977年 | 14篇 |
1976年 | 16篇 |
1975年 | 15篇 |
排序方式: 共有8124条查询结果,搜索用时 0 毫秒
131.
132.
尿毒症患者炎症反应与血脂的关系 总被引:4,自引:0,他引:4
目的 通过分析尿毒症患者慢性炎症指标与血脂的关系 ,探讨尿毒症的炎症反应影响心血管系统的途径。方法 测定 67例尿毒症患者慢性炎症指标血C 反应蛋白 (CRP)、白细胞介素 6(IL 6)、肿瘤坏死因子 α(TNF α)及血脂 ,并分析它们之间的关系。结果 2 6.87%的尿毒症患者CRP超过正常参考值 ( 5mg/L) ,CRP升高组血清甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDL C)、载脂蛋白B(ApoB)、载脂蛋白A1/载脂蛋白B(ApoA1/ApoB)、脂蛋白 (a) [Lp(a) ]高于CRP正常组 (P值均 <0 .0 5 ) ;血CRP与总胆固醇 (TC) (P <0 .0 5 )、TG、LDL C、ApoB、Lp(a)、血清肌酐 (Scr)、血尿素氮(BUN)呈正相关 (P值均 <0 .0 1) ,Logistic回归分析显示 ,CRP与TG、Lp(a)关系更为显著。结论 尿毒症患者存在慢性炎症状态 ,慢性炎症与脂代谢紊乱密切相关。 相似文献
133.
134.
目的 探讨妊娠期糖尿病(GDM)患者血清Betatrophin含量与机体糖脂代谢紊乱的关系.方法 前瞻性选取2018年12月至2020年1月在庆阳市人民医院进行糖耐量筛查并确诊为GDM的孕妇117例作为GDM组,同期在本院进行糖耐量筛查的健康孕妇100例作为正常对照组.比较2组孕妇的血清Betatrophin含量、外周... 相似文献
135.
目的:探讨瑞舒伐他汀对高脂诱导肥胖大鼠的血脂及白介素-6(IL-6)水平的影响。方法将30只雄性大鼠随机分成肥胖组(n=20)和对照组(n=10),分别用高脂饲料和普通饲料饲养14周,然后根据体重增加程度筛选出肥胖大鼠,并分别测定血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL- C)、低密度脂蛋白胆固醇(LDL- C)和IL-6的水平。对肥胖组进行瑞舒伐他汀干预,比较其干预前后血脂及IL-6的水平。结果肥胖组大鼠血清TG、TC、LDL- C和IL-6水平均显著高于对照组(均P<0.01),血清IL-6水平与TC、LDL- C呈显著正相关(r=0.72、0.71,均P<0.01);瑞舒伐他汀显著降低肥胖大鼠的血脂及IL-6水平。结论高脂诱导的肥胖大鼠血清IL-6明显升高,瑞舒伐他汀降低血脂的同时,能降低炎症因子IL-6的水平。 相似文献
136.
Maojian Chen Wenjian Huang Chao Wang Hao Nie Gang Li Ting Sun Fei Yang Yanxiang Zhang Kegang Shu Congyi Wang Quan Gong 《Clinical immunology (Orlando, Fla.)》2014,153(1):56-63
High-mobility group box 1 (HMGB1) is a nuclear factor that can also serve as an imflammatory mediator once released into extracellular milieu. Therefore, HMGB1 has been recognized to play a pivotal role in inflammatory diseases such as sepsis, acute lung injury, ischemia reperfusion injury and type 1 diabetes. Nevertheless, its impact on carbon tetrachloride (CCl4)-induced hepatic injury is yet to be elucidated. In the present report, we demonstrated evidence indicating that high levels of HMGB1 were not only present in the necrotic area of liver but also in the serum after CCl4 challenge. In line with these observations, administration of exogenous recombinant HMGB1 exacerbated CCl4-induced hepatic injury, while HMGB1 blocking antibody provided protection for mice against CCl4-induced acute liver injury as evidenced by the decrease of serum transaminase and reduction of hepatic tissues necrosis. Mechanistic studies revealed that blockade of HMGB1 attenuated CCl4-induced MDA accumulation along with improved SOD and GSH activity. Treatment of mice with HMGB1 neutralizing antibody also significantly inhibited the production of proinflammatory mediators TNF-α and IL-6 along with attenuated HMGB1 expression and its extracellular release. Together, our data suggest an essential role for HMGB1 in CCl4-induced acute liver injury, while HMGB1 neutralizing antibody could be served as an effective regimen for preventing CCl4-induced acute liver injury. 相似文献
137.
不同剂量辛伐他汀治疗冠心病的临床疗效观察 总被引:3,自引:0,他引:3
目的观察冠状动脉粥样硬化性心脏病患者使用不同剂量辛伐他汀的疗效、安全性、对血脂斑块生长及心血管事件的影响。方法将血脂总胆固醇(TC)≥4.68mmol/L和(或)低密度脂蛋白胆固醇(LDL-C)≥2.6 mmol/L,B超检查存在不同程度颈动脉斑块形成的临床诊断为冠心病的患者(126例)按随机原则分别入选辛伐他汀80mg组(强化治疗剂量)、40mg组与20mg组(常用处方剂量)。于服药后12周及24周复查血脂,B超复查颈动脉斑块,并对心血管事件作随访登记。结果辛伐他汀80mg、40mg与20mg均能有效地降低冠心病患者血清TC及LDL-C水平,其中80mg剂量组在降TC和降LDL-C及减少心血管事件发生率方面均明显优于20mg剂量组,40mg剂量组疗效介于两组之间,三者间均存在显著差异。80mg剂量组的颈动脉斑块缩小,而40mg剂量组及20mg剂量组无颈动脉斑块缩小。三种剂量在不良反应方面无明显差异。结论辛伐他汀强化治疗剂量在治疗冠心病方面明显优于常用处方剂量;强化治疗剂量可以逆转颈动脉斑块发展。 相似文献
138.
Marc Labetoulle Andrea Leonardi Mourad Amrane Dahlia Ismail Jean-Sébastien Garrigue Gerhard Garhöfer Maite Sainz de la Maza Christophe Baudouin 《Clinical therapeutics》2018,40(11):1894-1906
Purpose
Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established the efficacy and safety of once-daily 0.1% cyclosporin A cationic emulsion (CsA CE) in severe keratitis due to dry eye disease (DED). This article presents results from the Post-SANSIKA study, a 24-month extension of SANSIKA assessing the sustained efficacy of CsA CE after treatment discontinuation.Methods
Time to relapse (corneal fluorescein staining [CFS] score ≥4 [modified Oxford scale]) was assessed after treatment discontinuation in patients from the SANSIKA study who had CFS improvement from a score of 4 to ≤2 after 6 or 12 months of treatment with CsA CE.Findings
Of 62 patients who achieved a CFS score ≤2 at the end of the SANSIKA study, 38 did not relapse and 24 (39%) relapsed during the 24-month period after CsA CE discontinuation; the latter (relapse) group comprised 35% of patients initially treated with CsA CE for 12 months in SANSIKA versus 47% of those treated for 6 months only. Patients spent the most time during the extension study at CFS scores of 1 or 2 (median duration of 8.5 weeks and 14.7 weeks per year, respectively), indicating marked improvement, and less time at scores of 3, 4, or 5 (median time, 2.0 weeks, 0 weeks, and 0 weeks per year). Of 23 patients eligible for safety analysis (ie, patients who received the study treatment at least once), 12 (52.2%) reported a total of 26 ocular adverse events (AEs). Among these, 5 ocular AEs, reported in 5 patients (21.7%), were considered related to study treatment: 3 events of mild instillation site pain in 3 patients (13.0%) and eye discharge and foreign body sensation, each reported in 1 patient (4.3%). Only 1 systemic AE (nasal congestion), reported in 1 patient (4.3%), was considered related to study treatment. None of the AEs led to treatment discontinuation.Implications
The majority of patients who discontinued CsA CE after experiencing DED improvement in the SANSIKA study did not experience a relapse in this 24-month follow-up study; these patients spent the most time at CFS scores consistent with marked improvement. CsA CE had a favorable safety/tolerability profile over 2 years. Treatment for up to 12 months with CsA CE provides sustained improvements in patients with severe keratitis due to DED. EudraCT registration no. 2012-002066-12. 相似文献139.
Hee Jae Jung Young Seok Kim Sang Gyune Kim Yun Nah Lee Soung Won Jeong Jae Young Jang Sae Hwan Lee Hong Soo Kim Boo Sung Kim 《Clinical and molecular hepatology》2014,20(1):38-46
Background/Aims
Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment.Methods
In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of β cells (HOMA-β) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx).Results
A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0±11.2 years, mean±SD; non-SVR, 56.6±9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-β were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group.Conclusions
LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5). 相似文献140.
目的测定链脲佐菌素(STZ)诱导的不同周期精尿病大鼠对心肌缺血/再灌注(I/ R)损伤的影响及其与心肌脂质过氧化反应程度及血浆一氧化氮(NO)变化的关系。方法阻断和开放左冠状动脉前降支建立大鼠急性心肌I/R模型。用TTC染色测定大鼠心肌 I/R后梗死面积;用T/BARS法测定脂质过氧化反应程度;用硝酸还原酶法测定NO含量结果 STZ处理后2周,糠尿病组(2WD)心肌梗死面积比对照组(2WC)明显缩小,STZ处理后16周(16WD),梗死面积比对照组(16WC)增加;心脏组织的脂质过氧化物反应产物 2WD组较2WC组低,但是在16WD组中较16WC组显著增加;血浆NO水平2WD组较 2WC组增高,但是16WD组较16WC组显著减少。结论 STZ诱导的大鼠急、慢性期糖尿病对心肌I/R损伤呈现相反的作用。这可能是由于大鼠急、慢性期糖尿病相反的心肌脂质过氧化反应程度及NO改变而引起。 相似文献